Genericplus Pharmacy Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 10.54%
- Profit Growth -56.76%
- Ebitda 4.95%
- Net Worth 21.16%
- Total Assets -5.01%
About Genericplus Pharmacy
Genericplus Pharmacy Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 November 2019 (Five years and three months 2 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Piyush Jain, Ashok Jain, Kamlesh Jain, and One other member serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909MH2019PTC333079
-
Company No.
333079
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Nov 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Genericplus Pharmacy?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Piyush Jain
|
Director | 18-Apr-2023 | Current |
| Ashok Jain | Director | 25-Jan-2024 | Current |
|
Kamlesh Jain
|
Director | 25-Jan-2024 | Current |
|
Girish Jain
|
Director | 16-Nov-2019 | Current |
Financial Performance of Genericplus Pharmacy.
Genericplus Pharmacy Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 10.54% increase. The company also saw a substantial fall in profitability, with a 56.76% decrease in profit. The company's net worth Soared by an impressive increase of 21.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genericplus Pharmacy?
Unlock access to Genericplus Pharmacy's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Johnlee Pharmaceuticals Private LimitedGirish Jain is a mutual person
-
Baker & Davis Private LimitedPiyush Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genericplus Pharmacy?
Unlock and access historical data on people associated with Genericplus Pharmacy, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genericplus Pharmacy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genericplus Pharmacy's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
